Coreceptor Usage of Sequential Isolates from Cynomolgus Monkeys Experimentally Infected with Simian Immunodeficiency Virus (SIVsm)

Vödrös, Dalma; Thorstensson, Rigmor; Biberfeld, Gunnel; Schols, Dominique; Clercq, Erik De; Fenyõ, Éva Mária

doi:10.1006/viro.2001.1164

Cited by 15 publications

(7 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…HIV-2 shares this property with SIV (9,56,60), which differentiates these two viruses from HIV-1 (8,55,59,61). The capacity to use these two chemokine receptors, and also the use of the unidentified U87 coreceptor, may explain the broader tropism of HIV-2 than HIV-1 observed in vitro (14,36).…”

Section: Vol 79 2005 Hiv-2 Coreceptor Use In Viremic and Aviremic Imentioning

confidence: 99%

CCR5, GPR15, and CXCR6 Are Major Coreceptors of Human Immunodeficiency Virus Type 2 Variants Isolated from Individuals with and without Plasma Viremia

Blaak¹,

Boers²,

Gruters³

et al. 2005

J Virol

View full text Add to dashboard Cite

Human immunodeficiency virus type 2 (HIV-2) is generally considered capable of using a broad range of coreceptors. Since HIV-2 variants from individuals with nonprogressive infection were not studied previously, the possibility that broad coreceptor usage is a property of variants associated with progressive infection could not be excluded. To test this, we determined the coreceptor usage of 43 HIV-2 variants isolated from six long-term-infected individuals with undetectable plasma viremia. Using GHOST indicator cells, we showed for the first time that the only coreceptors efficiently used by low-pathogenic HIV-2 variants are CCR5, GPR15 (BOB), and CXCR6 (BONZO). Surprisingly, control HIV-2 variants (n ‫؍‬ 45) isolated from seven viremic individuals also mainly used these three coreceptors, whereas use of CCR1, CCR2b, or CCR3 was rare. Nearly a quarter of all HIV-2 variants tested could infect the parental GHOST cells, which could be partially explained by CXCR4 usage. Use of CXCR4 was observed only for HIV-2 variants from viremic individuals. Thirty-eight variants from aviremic and viremic HIV-2-infected individuals were additionally tested in U87 cells. All except one were capable of infecting the parental U87 cells, often with high efficiency. When virus production in parental cells was regarded as background in the coreceptor-transduced cell lines, the results in U87 cells were largely in agreement with the findings in GHOST cells. HIV-2 isolates from aviremic individuals commonly use as coreceptors CCR5, GPR15, and CXCR6, as well as an unidentified receptor expressed by U87 cells. Broad coreceptor usage, therefore, does not appear to be associated with pathogenicity of HIV-2.

show abstract

Section: Vol 79 2005 Hiv-2 Coreceptor Use In Viremic and Aviremic Imentioning

confidence: 99%

CCR5, GPR15, and CXCR6 Are Major Coreceptors of Human Immunodeficiency Virus Type 2 Variants Isolated from Individuals with and without Plasma Viremia

Blaak¹,

Boers²,

Gruters³

et al. 2005

J Virol

View full text Add to dashboard Cite

show abstract

“…With the use of 59 HIV-1 isolates and 6 sublines of the GHOST(3) cells (the parental cells and 5 cell lines transfected with different coreceptors) the assay has been validated. The same validation applies to SIV and the accompanying paper (Vödrös et al, 2001) describes the coreceptor use of 20 sequentially obtained SIVsm isolates. R5 monotropic HIV-1 isolates were characteristically infecting CCR5-expressing cells only.…”

Section: Discussionmentioning

confidence: 96%

Quantitative Evaluation of HIV-1 Coreceptor Use in the GHOST(3) Cell Assay

et al. 2001

Self Cite

View full text Add to dashboard Cite

The utility of the GHOST(3) cell assay has been evaluated for testing coreceptor use of primary human immunodeficiency virus type 1 (HIV-1) isolates. GHOST(3) cells were derived from the human osteosarcoma cell line, HOS, and have been engineered to stably express CD4 and one or another of the chemokine receptors CCR3, CCR5, CXCR4, Bonzo, or the orphan receptor BOB. The indicator cell line carries the HIV-2 long terminal repeat-driven green fluorescence protein (GFP) gene, which becomes activated upon infection with HIV or simian immunodeficiency virus. Viral entry is followed by Tat activation of transcription and GFP becomes expressed. Infected cells can be detected 2 or 3 days after infection by simple fluorescence microscopic observation. This simplicity is the main advantage of the GHOST(3) cell system and makes it particularly suitable for screening of a large number of isolates. In addition, the efficiency of coreceptor use can be accurately quantitated with flow cytometric analysis. Here, we evaluated the coreceptor use of 59 primary HIV-1 isolates of different subtypes.

show abstract

“…LSYRWPCRff LSYRWPCRff Tat peptide analogs encompassing the Tat core domain (amino acid residues [36][37][38][39][40][41][42][43][44][45][46][47][48][49][50] or the basic domain (amino acids 48-56: RKKRRQRRR) have been reported to inhibit HIV replication, and, not unexpectedly, these Tat peptide analogs also block the Tat transactivation process [27,28]. The nonamer peptoid CGP-64222 (Fig.…”

Section: The Bicyclam Amd3100 As Compared To Other Cxcr4 Antagonistsmentioning

confidence: 99%

“…Co-receptor use of clinical HIV strains in the absence (-) or presence (+) of AMD3100 [34]. up in a convenient [GHOST [3]] cell assay [40] with AMD3100 as probe [41].…”

Section: The Bicyclam Amd3100 As a Tool To Probe Cxcr4 Usage By Hiv Smentioning

confidence: 99%

Potential Clinical Applications of the CXCR4 Antagonist Bicyclam AMD3100

Clercq

2005

MRMC

Self Cite

View full text Add to dashboard Cite

The bicyclam AMD3100 (originally called JM3100), in which the two cyclam rings are tethered by an aromatic bridge, emanated from JM2763, where the two cyclam moieties are tethered by an aliphatic linker - JM2763 in turn originated from JM1657, where the cyclam rings are directly linked to one another via a C-C bridge, and which was identified as an impurity, showing anti-HIV activity, in a commercial cyclam preparation. AMD3100 proved very effective against HIV-1 and HIV-2, inhibiting virus replication within the nM range, without toxicity for the host cells at concentrations that were > 100,000-fold higher than those required to inhibit HIV replication. The anti-HIV activity of AMD3100 appeared to be confined to the T-lymphotropic (X4) HIV strains, i.e. those strains that use the CXCR4 receptor to enter their target cells, and AMD3100 as of today still stands as one of the most potent and selective CXCR4 antagonists ever discovered. Hence, AMD3100 was found to interfere with a number of (patho)physiological processes which depend on the interaction of CXCR4 with its natural ligand, stromal derived factor (SDF-1) and which play an important role in rheumatoid, allergic and malignant diseases. AMD3100 has been shown to mobilize CD34+ stem cells from the bone marrow into the bloodstream and has also been shown to augment migration of bone marrow-derived endothelial progenitor cells into sites of neovascularization after myocardial infarction. Currently, AMD3100 is actively pursued as a stem cell mobilizer for transplantation in patients with multiple myeloma and non-Hodgkin's lymphoma.

show abstract

Coreceptor Usage of Sequential Isolates from Cynomolgus Monkeys Experimentally Infected with Simian Immunodeficiency Virus (SIVsm)

Cited by 15 publications

References 55 publications

CCR5, GPR15, and CXCR6 Are Major Coreceptors of Human Immunodeficiency Virus Type 2 Variants Isolated from Individuals with and without Plasma Viremia

CCR5, GPR15, and CXCR6 Are Major Coreceptors of Human Immunodeficiency Virus Type 2 Variants Isolated from Individuals with and without Plasma Viremia

Quantitative Evaluation of HIV-1 Coreceptor Use in the GHOST(3) Cell Assay

Potential Clinical Applications of the CXCR4 Antagonist Bicyclam AMD3100

Contact Info

Product

Resources

About